News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
746,433 Results
Type
Article (44027)
Company Profile (312)
Press Release (702076)
Multimedia
Podcasts (122)
Webinars (22)
Section
Business (211070)
Career Advice (2115)
Deals (36777)
Drug Delivery (134)
Drug Development (83485)
Employer Resources (176)
FDA (16879)
Job Trends (15520)
News (357581)
Policy (34146)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2629)
Accelerated approval (42)
Adcomms (27)
Allergies (166)
Alliances (51587)
ALS (196)
Alzheimer's disease (1762)
Antibody-drug conjugate (ADC) (380)
Approvals (17193)
Artificial intelligence (617)
Autoimmune disease (226)
Automation (50)
Bankruptcy (373)
Best Places to Work (11769)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (187)
Bladder cancer (177)
Brain cancer (67)
Breast cancer (695)
Cancer (5383)
Cardiovascular disease (458)
Career advice (1797)
Career pathing (40)
CAR-T (303)
CDC (56)
Celiac Disease (2)
Cell therapy (811)
Cervical cancer (41)
Clinical research (71813)
Collaboration (1946)
Company closure (4)
Compensation (1279)
Complete response letters (77)
COVID-19 (2798)
CRISPR (104)
C-suite (1003)
Cystic fibrosis (153)
Data (7085)
Decentralized trials (3)
Denatured (37)
Depression (155)
Dermatology (57)
Diabetes (555)
Diagnostics (6911)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (302)
Drug pricing (213)
Drug shortages (32)
Duchenne muscular dystrophy (268)
Earnings (92792)
Editorial (63)
Employer branding (21)
Employer resources (155)
Events (121301)
Executive appointments (1058)
FDA (20330)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1627)
Gene editing (217)
Generative AI (53)
Gene therapy (672)
GLP-1 (1063)
Government (4836)
Grass and pollen (7)
Guidances (397)
Healthcare (19104)
HIV (73)
Huntington's disease (53)
IgA nephropathy (93)
Immunology and inflammation (284)
Immuno-oncology (82)
Indications (158)
Infectious disease (3111)
Inflammatory bowel disease (208)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (278)
Interviews (328)
IPO (16927)
IRA (57)
Job creations (4072)
Job search strategy (1502)
JPM (65)
Kidney cancer (18)
Labor market (92)
Layoffs (582)
Leadership (36)
Legal (8425)
Liver cancer (99)
Longevity (29)
Lung cancer (720)
Lymphoma (409)
Machine learning (53)
Management (60)
Manufacturing (947)
MASH (182)
Medical device (13936)
Medtech (14013)
Mergers & acquisitions (21009)
Metabolic disorders (1444)
mRNA (185)
Multiple sclerosis (172)
NASH (18)
Neurodegenerative disease (387)
Neuropsychiatric disorders (101)
Neuroscience (3177)
Neurotech (1)
NextGen: Class of 2026 (6647)
Non-profit (4573)
Now hiring (73)
Obesity (684)
Opinion (300)
Ovarian cancer (186)
Pain (245)
Pancreatic cancer (255)
Parkinson's disease (338)
Partnered (34)
Patents (560)
Patient recruitment (593)
Peanut (63)
People (61264)
Pharmaceutical (85)
Pharmacy benefit managers (34)
Phase 1 (22287)
Phase 2 (31588)
Phase 3 (23660)
Pipeline (7160)
Policy (318)
Postmarket research (2655)
Preclinical (9468)
Press Release (68)
Prostate cancer (276)
Psychedelics (51)
Radiopharmaceuticals (309)
Rare diseases (1023)
Real estate (6309)
Recruiting (72)
Regulatory (25865)
Reports (54)
Research institute (2455)
Resumes & cover letters (362)
Rett syndrome (32)
RNA editing (18)
RSV (85)
Schizophrenia (172)
Series A (272)
Series B (203)
Service/supplier (11)
Sickle cell disease (109)
Special edition (25)
Spinal muscular atrophy (167)
Sponsored (46)
Startups (3775)
State (2)
Stomach cancer (19)
Supply chain (119)
Tariffs (97)
The Weekly (83)
Vaccines (1085)
Venture capital (100)
Weight loss (445)
Women's health (110)
Worklife (19)
Date
Last 7 days (644)
Last 30 days (2489)
Last 365 days (30352)
2026 (8102)
2025 (30678)
2024 (35761)
2023 (40629)
2022 (51798)
2021 (56329)
2020 (54791)
2019 (47397)
2018 (35770)
2017 (33136)
2016 (32662)
2015 (38615)
2014 (32516)
2013 (27631)
2012 (29731)
2011 (30487)
2010 (28497)
Location
Africa (802)
Alabama (90)
Alaska (7)
Arizona (338)
Arkansas (15)
Asia (42390)
Australia (6788)
California (12318)
Canada (3531)
China (1265)
Colorado (525)
Connecticut (523)
Delaware (370)
Europe (91079)
Florida (1856)
Georgia (393)
Hawaii (3)
Idaho (62)
Illinois (973)
India (83)
Indiana (568)
Iowa (22)
Japan (499)
Kansas (130)
Kentucky (44)
Louisiana (40)
Maine (73)
Maryland (1491)
Massachusetts (8847)
Michigan (349)
Minnesota (678)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (136)
New Hampshire (82)
New Jersey (3287)
New Mexico (29)
New York (3257)
North Carolina (1578)
North Dakota (8)
Northern California (6080)
Ohio (367)
Oklahoma (23)
Oregon (46)
Pennsylvania (2501)
Puerto Rico (26)
Rhode Island (50)
South America (1178)
South Carolina (77)
South Dakota (1)
Southern California (4843)
Tennessee (199)
Texas (1939)
United States (43759)
Utah (370)
Vermont (1)
Virginia (307)
Washington D.C. (80)
Washington State (990)
West Virginia (4)
Wisconsin (124)
Wyoming (2)
746,433 Results for "crinetics pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 6, 2025
·
11 min read
Press Releases
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
January 5, 2026
·
2 min read
Press Releases
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
January 23, 2026
·
7 min read
Press Releases
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 10, 2025
December 11, 2025
·
2 min read
Press Releases
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
·
2 min read
Press Releases
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
October 6, 2025
·
2 min read
Press Releases
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
December 12, 2025
·
7 min read
Press Releases
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 10, 2025
October 13, 2025
·
2 min read
Press Releases
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 8, 2025
·
11 min read
Press Releases
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
November 21, 2025
·
8 min read
Previous
2 of 74,644
Next
